Posted by Michael Wonder on 09 Mar 2020
FDA approves first treatment for group of progressive interstitial lung diseases
9 March 2020 - The U.S. FDA today approved Ofev (nintedanib) oral capsules to treat patients with chronic fibrosing interstitial lung diseases with a progressive phenotype.
It is the first FDA approved treatment for this group of fibrosing lung diseases that worsen over time.
Ofev’s safety and effectiveness to treat chronic fibrosing interstitial lung disease with a progressive phenotype in adults was evaluated in a randomised, double-blind, placebo-controlled study of 663 adults.
